AbbVie presents Phase 3 AFFIRM data showing endoscopic remission with SKYRIZI in Crohn's disease
The study reported that 35.8% of patients achieved endoscopic remission and 36.6% achieved ulcer-free endoscopy after subcutaneous SKYRIZI versus 10.2% and 10.2% with placebo. Safety findings through week 24 were consistent with the known safety profile of risankizumab, with no new safety signals.
Primary source
Company press release (PR Newswire), October 13, 2026
AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease
Machine-summarized from the source above; not independently reported. How we use automation